#1VEGA-1 Phase 2 Topline Results Conference Call June 30, 2021 Ocuphire Restore Vision & Clarity#22 Disclosures and Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire Pharma, Inc.'s ("Ocuphire" or the "Company") product candidates and future milestones, including the potential for Nyxol to be a "best in class" presbyopia drop. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) timing or ability for the company to achieve its targeted milestones; (ii) the success and timing of regulatory submissions and pre-clinical and clinical trials; (iii) regulatory requirements or developments; (iv) changes to clinical trial designs and regulatory pathways; (v) changes in capital resource requirements; (vi) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vii) legislative, regulatory, political and economic developments, and (viii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by the Company from time to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or incorporated by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or completeness of any such information. This presentation may not be reproduced or provided to any other person (other than your advisor) without our prior written consent. By accepting delivery of this presentation, you agree to the foregoing and agree to return this presentation and any documents related thereto and any copies thereof to us or to destroy the same if you do not make an investment in any securities. The information contain within this presentation shall not, except as hereinafter provided, without the prior written consent of the Company, be disclosed by you or your representatives in any manner whatsoever, in whole or in part, and shall not be used by you or your representatives other than for the purpose of evaluating the transaction described herein. By accepting delivery of this presentation you further acknowledge and agree aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities by any person who has received material, nonpublic information from the issuer of the securities or any affiliate thereof and on the communication of such inform tion to any other person when it is reasonably foreseeable that such other person is likely to purchase or sell such securities in reliance on such information for so long as the information remains material and non- public. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. November 6, 2020 NASDAQ CONGRATULATES OCUPHIRE ON RECENT LISTING AND CAPITAL RAISE OCUPHIRE PHARMA Ocuphire OCUP NasdaqListed Nasdaq J#33 Agenda and Participants Phase 2 Trial Topline Readout As Planned In 2Q21 ● ● ● Topline VEGA-1 Phase 2 Clinical Trial Results for Nyxol and Low-Dose Pilocarpine in Presbyopia Presbyopia Market Opportunity Future Milestones Q&A Participants Mina Sooch, MBA, President and CEO Mitch Brigell, PhD, Head of Clinical Development Jay Pepose, MD, Medical Advisory Board & Corporate Board Member Susan Benton, Corporate Board Member Charlie Hoffmann, MBA, VP of Corporate Development and Operations Amy Rabourn, MAcc, VP of Finance Ocuphire PHARMA#44 Ocuphire Pipeline & Upcoming Milestones Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated Over The Next Year Ocuphire-Focused Development Partnering- Focused Development Product Candidate 0.75% NyxolⓇ Eye Drop 0.75% NyxolⓇ Eye Drop APX3330 Oral Pill Indication APX2009 Intravitreal Reversal of Mydriasis (RM) 0.75% Nyxol® + Low- Dose 0.4% Pilocarpine Presbyopia (P) Eye Drops Dim Light or Night Vision Disturbances (NVD) Diabetic Retinopathy (DR)/ Macular Edema (DME) DME, Wet Age-Related Macular Degeneration (wAMD) Development Stage Pre-clinical Phase 1 Phase 2 Phase 3 Positive Data Readout Positive Data Readout Anticipated Milestones Initiated Phase 3 MIRA-2 trial 4Q20; Topline data reported in 1Q21 (n=185) Initiate Phase 3 MIRA-3 trial 2H21; Data expected in early 2022 (n=330) Initiate Pediatric trial 2H21; Data expected in early 2022 (n=20) Initiated Phase 3 LYNX-1 trial 4Q20; Data expected in 3Q21 (n=160) Initiated Phase 2 VEGA-1 trial 1Q21; Topline data reported in 2Q21 (n=150) Initiated Phase 2 ZETA-1 trial Apr21; Data expected by early 2022 (n=100) Next steps: IND enabling studies (with partner funding) Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phento lamine Mesylate Ophthalmic Solution) Ocuphire PHARMA#5P LO 5 Product Profile: Nyxol + Low-Dose Pilocarpine (LDP) Combo Moderate Use of Iris Dilator And Iris Sphincter Muscles To Improve Near Vision 0.75% Nyxol F O 0.4% 0.4% LDP Source: Ocuphire Clinical Trials (completed) Iris Dilator Muscle Inhibition Iris Sphincter Muscle Activation ● ● ● ● ● Active ingredient approved decades ago 505(b)(2) Novel MOA on iris dilator with 24+ hour durability with moderate 1+mm pupil reduction Chronic daily dosing of Nyxol at bedtime demonstrated no daytime redness Well-tolerated with no systemic effects Stable, preservative-free, single use vial Ⓡ Pilocarpine Opal Solution, US 0.4% • Active ingredient approved decades ago 505(b)(2) Known MOA on sphincter muscle with more potent miotic effects at approved doses (1%, 2%, 4%) Chronic daily dosing in daytime Low concentration avoids known tolerability issues: headache and browache ➤ redness Nyxol + LDP accommodative spasm causing loss of distance vision especially at night Ocuphire PHARMA#6P CO 6 Potential 'Best in Class' Presbyopia Drop Topline Results From Vega-1 Were Positive... Nyxol + LDP Presbyopia Treatment is Differentiated: Statistically significant efficacy data ✓ Favorable safety profile ✓ Comfort and tolerability ✓ Fast onset ✔ Long duration ✓ Maintain good distance visual acuity (night/day) ✓ Novel tunable pupil modulation Ocuphire PHARMA#77 + NyxolⓇ RM NVD P Reversal of Mydriasis. Night Vision Disturbances Presbyopia H Ocuphire PHARMA Phentolamine Mesylate OH • CH3SO³H#88 Ocuphire Clinical trial NCT#04675151 PHARMA Topline VEGA-1 Phase 2 Results Randomized, Multi-Center, Double-Masked, Placebo- Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) + 0.4% Low Dose Pilocarpine (LDP) for the Treatment of Presbyopia#9P 9 Objectives and Key Eligibility Criteria VEGA-1 (OPI-NYXP-201) Phase 2 Trial Evaluating Nyxol + LDP for Treatment of Presbyopia Key Objectives PRIMARY To evaluate the efficacy of Nyxol + LDP to improve DCNVA compared to Placebo alone in presbyopia subjects ● KEY SECONDARY • To evaluate the ocular and systemic safety of Nyxol + LDP and each component individually • To evaluate multiple secondary visual acuity and pupil diameter endpoints Key Eligibility Criteria INCLUSION Males or females ≥ 40 and ≤ 64 years of age. BCDVA of 20/20 or better under photopic conditions • DCNVA of 20/50 or worse under photopic conditions Binocular best-corrected near VA is 20/25 or better EXCLUSION Clinically significant ocular disease Recent or current evidence of ocular infection or inflammation in either eye Clinical trial NCT#04675151. BCDVA is Best Corrected Distance Visual Acuity and DCNVA is Distance Corrected Near Visual Acuity Ocuphire PHARMA#10P 10 Presbyopia VEGA-1 Phase 2 Design Randomized, Double-Masked, Placebo-Controlled One-Week Trial VEGA-1 17 US sites 150 presbyopic patients 0.75% Nyxol 4 arms Placebo Randomization Clinical trial NCT#04675151 Visit 1 Baseline Baseline Baseline Baseline Screening Evening Dosing (3-4 doses) Nyxol Nyxol Placebo Placebo Visit 2 (3-6 Days Later) LDP Drop No Treatment LDP Drop No Treatment Treatment Arms Nyxol + LDP Nyxol Alone LDP Alone Placebo Alone Phase 2 Enrollment Completed Feb to May 2021 – 150 Subjects Reporting Topline Results as Guided by End of 2Q21 Primary: % of subjects with ≥ 3 lines of improvement in distance- corrected near visual acuity comparing Nyxol + LDP vs placebo alone at 1 hour Endpoints Secondary: ● ● % of subjects with ≥ 2 and 23 lines gained at time points from 30 min to 6 hours in photopic and mesopic lighting comparing Nyxol + LDP vs placebo, Nyxol alone, and LDP alone No loss of distance vision Pupil diameter at time points Safety and tolerability (redness) Ocuphire PHARMA#11P 11 Patient Population - Subject Disposition Per Protocol Population, mITT, And Safety Population Are Essentially Identical ● • ● All Randomized Population (ARP) Safety Population (SP) Modified Intention to Treat Population (mITT) Per Protocol Population (PP) Completed Study Discontinued Study Early Placebo Alone N (%) 45 Source: VEGA-1 TLR Table 14.1.1 Subject Disposition 45 (100%) 44 (98%) 43 (96%) 44 (98%) 1 (2%) Nyxol Alone N (%) 30 30 (100%) 30 (100%) 30 (100%) 30 (100%) 0 LDP Alone N (%) 31 31 (100%) 31 (100%) 31 (100%) 31 (100%) 0 Nyxol+LDP N (%) 44 44 (100%) 43 (98%) 43 (98%) 43 (98%) 1 (2%) Total N (%) 150 150 (100%) 148 (99%) 147 (98%) 148 (99%) 2 (1%) 148/150 subjects completed the study (mITT) Only a single subject difference between mITT and PP population Per Statistical Analysis Plan, all analyses performed on PP population with results being nearly identical for mITT Ocuphire PHARMA#12P 12 Demographics (PP Population) Treatment And Placebo Arms Were Balanced In This Phase 2 Clinical Trial Age (years): Median (Range) Sex: Male n (%) Female n (%) Race: White n (%) African American n (%) Asian n (%) Other* n (%) Dark Iris Color: n (%) Placebo Alone N=43 52 (42-62) 15 (35%) 28 (65%) 37 (86%) 4 (9%) 2 (5%) 0 (0%) 18 (42%) 25 (58%) Nyxol Alone N=30 54 (41-60) 7 (23%) 23 (77%) 26 (87%) 0 (0%) 0 (0%) 1 (3%) 12 (40%) 18 (60%) Light Iris Color: n (%) * includes American Indian or Alaska Native; Native Hawaiian or Other Pacific Islander Source: VEGA-1 TLR Table 14.1.2.2 Demographics and Baseline Characteristics (PP Population) LDP Alone N=31 52 (44-64) 13 (42%) 18 (58%) 28 (90%) 1 (3%) 6 (6%) 1 (3%) 12 (39%) 19 (61%) Nyxol+LDP N=43 53 (43-63) 5 (12%) 38 (88%) 40 (93%) 0 (0%) 6 (6%) 0 (0%) 18 (42%) 25.1 (58%) Total N=147 53 (41-64) 40 (27%) 107 (73%) 131 (89%) 3 (2%) 11 (5%) 2 (1%) 60 (41%) 87 (59%) Ocuphire PHARMA#13P 13 Baseline Characteristics Study Eye (PP Population) Treatment Arms Were Balanced Across Key Ocular Measurements Baseline Characteristic Photopic DCNVA Mean Letters read-Binocular (Snellen Equiv.) 70 letters = 20/20 Photopic BCDVA Mean Letters read-Binocular (Snellen Equiv.) 55 letters = 20/20 Photopic Pupil Diameter Mean (mm) Mesopic Pupil Diameter Mean (mm) IOP (mmHg) Placebo Alone N=43 46 (20/63) 62 (20/15) 4.3 5.1 13.5 Nyxol Alone N=30 45 (20/63) 61 (20/15) 4.5 5.0 14.8 LDP Alone N=31 48 (20/63) 60 (20/15) 4.3 5.0 13.9 Source: VEGA-1 TLR Table 14.1.2.2 Demographics and Baseline Characteristics (PP population). Snellen Conversion Chart. Nyxol+LDP N=43 46 (20/63) 61 (20/15) 4.3 5.1 14.4 Total N=147 46 (20/63) 61 (20/15) 4.3 5.1 14.1 Ocuphire PHARMA#14P 14 Primary Endpoint: % of Subjects ≥ 15 Letter Gain in Photopic DCNVA at 1 Hour Primary Endpoint Was Met For Nyxol + LDP Gaining ≥ 15 Letters Near Vision In PP Population Percent of Subjetcts (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 15 Letters DCNVA Improvement from Baseline Binocular (PP Population) p=0.003 61% 28% 1 VEGA-1 Phase 2 Trial Time (Hours) Placebo (n=43) Nyxol+LDP (n=43) 33% Placebo Adjusted Responders Percent of Subjects (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 15 Letters DCNVA Improvement from Baseline Binocular (mITT) p=0.003 61% 27% 1 Time (Hours) Placebo (n=44) Nyxol+LDP (n=43) Source: VEGA-1 TLR Table 14.2.1.1 (mITT) and 14.2.1.2 (PP)Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point. 15 letters is 3 lines. 34% Placebo Adjusted Responders, Ocuphire PHARMA#15P 15 Secondary Endpoint: % of Subjects ≥ 10 Letter Gain In Photopic DCNVA At 1 Hour Many Subjects Treated With Nyxol + LDP Gained A Clinically Meaningful ≥ 10 Letters Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 10 Letters DCNVA Improvement from Baseline Binocular (PP Population) p=0.006 79% 49% 1 Time (Hours) Placebo (n=43) VEGA-1 Phase 2 Trial 30% Placebo Adjusted Responders Nyxol+LDP (n=43) Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 10 Letters DCNVA Improvement from Baseline Binocular (mITT) p=0.007 79% 50% 1 Time (Hours) Placebo (n=44) 29% Placebo Adjusted Responders Nyxol+LDP (n=43) Source: VEGA-1 TLR Table 14.2.1.1 (mITT) and 14.2.1.2 (PP) Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point. 10 letters is 2 lines. Ocuphire PHARMA#16P 16 Secondary Endpoint: % of Subjects ≥ 15 Letter Gain At All Timepoints Nyxol + LDP Had Strong Response With ≥ 15 Letter Gain From 30 Min To 6 Hours Percent of Subjects (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subject with ≥ 15 Letters DCNVA Improvement from Baseline Binocular p=0.09 33% 16% 0 Rapid onset of efficacy p=<0.0001 14% 61% VEGA-1 Phase 2 Trial 0.5 p=0.003 28% 61% 1 p=<0.0001 Placebo (n=43) 16% 63% 2 Time (Hours) p=0.02 47% 21% 3 Nyxol+LDP (n=43) p=0.02 21% 47% 4 Durable benefit over 6 hours p=0.06 37% 19% со 6 Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects with Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines. Ocuphire PHARMA#17P Percent of Subjects (%) Secondary Endpoint: % of Subjects ≥ 15 Letter Gain DCNVA (Monocular) Similar Results Were Seen Monocularly For Study Eye And Fellow Eye On Primary Endpoint Study Eye Percent of Subjects with ≥15 Letters DCNVA Improvement from Baseline 100% 90% 80% 70% 60% 50% 40% p=0.1 28% 30% 20% 10% 0% 14% 0 p=0.08 44% 26% 0.5 p=0.0008 p=0.002 54% 56% 16% 1 21% Placebo (n=43) 2 p=0.3 p=0.01 42% 40% 28% Time (Hours) 3 Nyxol+LDP (n=43) 16% VEGA-1 Phase 2 Trial 4 p=0.2 33% 19% 6 Percent of Subjects (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Fellow Eye Percent of Subjects with ≥15 Letters DCNVA Improvement from Baseline p=0.3 21% 12% 0 p=0.001 p=0.001 49% 49% 14% 0.5 14% 1 Placebo (n=43) 17 Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point (PP Population) p=0.0003 49% p=0.02 p=0.02 40% 40% 9% 2 16% Time (Hours) 3 Nyxol+LDP (n=43) 16% 4 p=0.09 21% 7% 6 Ocuphire PHARMA#18P 18 2nd Endpoint: % of Subjects ≥ 15 Letter Gain In Near & ≤ 5 Letter Loss In Distance Phase 3 Approval Endpoint Also Showed Early Onset Of Near Vision Gain Without Loss of Distance Statistics Compared to Nyxol+LDP arm Powered for comparison to placebo whereas comparison to component arms were designed to inform the Phase 3 sample size 70% Percent of Subjects (%) 60% 50% 40% 30% 20% 10% 0% p=<0.0001 14% 61% p=0.03 33% 0.5 VEGA-1 Phase 2 Trial Percent of Subjects with 15 Letter Improvement in DCNVA and ≤ 5 Letter Loss in BCDVA Binocular p=0.008 26% Placebo (n=43) p=0.004 28% 61% Time Nyxol+LDP (n=43) 1 p=0.01 30% p=0.2 42% (Hours) Nyxol (n=30) p=<0.0001 14% LDP (n=31) 63% p=0.0009 20% 2 p=0.06 39% Source: VEGA-1 TLR Table 14.2.2.2 Percent of Subjects with >= 15 Letters of Improvement in Photopic DCNVA and < 5 Letters of Loss in Photopic Binocular BCDVA by Time Point (PP Population) Ocuphire PHARMA#19P 19 Percent of Subjects (%) Change in Photopic and Mesopic BCDVA at the 1-Hour Timepoint Treatment With Nyxol And/Or LDP Did Not Reduce BCDVA And Had A Modest Beneficial Effect 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects With Improvement or Loss From Baseline in Photopic BCDVA at 1 Hour 91% *p<0.05 9% 28% 20% 19% 72% 77% 74% >= 5 Letters Placebo (n=44) Nyxol+LDP (n=43) Nyxol (n=30) Within 5 Letters VEGA-1 Phase 2 Trial 0% 0% 3% <= -5 Letters LDP (n=31) 7% Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects With Improvement or Loss From Baseline in Mesopic BCDVA at 1 Hour 84% 9% 23% 27% 39% >= 5 Letters Placebo (n=43) 72% 73% 55% Within 5 Letters Nyxol+LDP (n=43) Nyxol (n=30) Source: VEGA-1 TLR Table 14.2.8.1 and 14.2.10.1 Percent of Subjects With Improvement or Loss From Baseline in Photopic and Mesopic BCDVA by Time Point (PP) 7% 5% 0% <= -5 Letters LDP (n=31) 7% Ocuphire PHARMA#20P 20 Secondary Endpoint: Mean Pupil Diameter Over Time Achieved Pupil Size ~2mm In Nyxol+LDP Consistent With 3-line Improvement In Near Vision 5.0 4.0 Mean Pupil Diameter (mm) 3.0 ≥2.0 1.0 4.8 4.4 4.3 4.2 Daily Evening Nyxol Dosing 12 hr minimum interval to Time 0 *** 4.5 3.1 Baseline 4.3 0 3.2 *** *** *** 4.5 3.2 3.0 N 2.4 *** T *** ** HH 4.4 1 3.2 2.5 2.1 Best Eye Mean Pupil Diameter *** *** ** H КН 4.3 3.4 2.7 2.3 *** *** 3.3 *** 4.4 3 3.1 2.5 *** T *** *** 4.4 2 -LDP (n=31) Time (Hours) -Placebo (n=43) Nyxol+LDP (n=43)-Nyxol (n=30) Source: VEGA-1 TLR Table 14.2.12.1 Observed Values and Change from Baseline in Photopic Pupil Diameter by Time Point (PP Population) 3.3 4 3.3 2.7 *** 4.6 Statistics Compared to Nyxol+LDP arm *p<0.05 **p<0.01 ***p<0.0001 5 *** 3.6 ** 6 3.3 2.9 Ocuphire PHARMA#21P 21 Secondary Endpoint: Safety Findings Nyxol+LDP Combination Was Well Tolerated With A Favorable Safety Profile In VEGA-1 Trial Total Treatment Emergent Adverse Events (n) TEAES by Severity (n [%]) Mild Moderate Severe AES Occurring in ≥ 5% of subjects (n [%]) Instillation Site Pain (Mild) Instillation Site Erythema (Mild) Conjunctival Hyperemia (Mild) Eye Disorders (Mild) Placebo Alone Nyxol Alone n=45 n=30 4 1 (2.2%) 1 (2.2%) 0 (0%) 1 (2.2%) 0 (0%) 0 (0%) 1 (2.2%) 18 6 (20%) 0 (0%) 0 (0%) 3 (10%) 3 (10%) 2 (6.7%) 2 (6.7%) LDP Alone n=31 13 6 (19.4%) 0 (0%) 0 (0%) 0 (0%) 2 (6.5%) 0 (0%) 4 (12.9%) Nyxol+LDP n=44 50 13 (29.5%) 1 (2.3%) 1 (2.3%) 4 (9.1%) 5 (11.4%) 2 (4.5%) 5 (11.4%) Source: VEGA-1 TLR Table 14.3.1.1 Overall Summary of Treatment Emergent Adverse Events (TEAE) (Safety Population) Table 14.3.1.3 Treatment-Emergent Adverse Events (TEAE) by System Organ Class, Preferred Term, and Severity (Safety Population) ● ● ● No deaths, no serious AEs, and 1 withdrawal due to AEs (on Nyxol alone) 0% Headaches or Browaches reported for Nyxol+LDP and Nyxol alone Only 1 subject in LDP alone arm reported mild headache Almost all AEs were mild and most common was mild instillation site discomfort Distance visual acuity not adversely affected (as shown earlier) No change in IOP Ocuphire PHARMA#22P 22 Tolerability: Conjunctival Hyperemia (Redness) Score Minor Change (0.5 Point) In Redness Score Over The First 2 Hours In LDP Arms 4 Mean Hyperemia Score (4-point scale) 2 3 0 0 Mean Hyperemia Score (4-point Scale) Over Time 0.5 Placebo Alone (N=45) 1 2 Time (Hours) Nyxol + LDP (N=44) 3 4 -Nyxol Alone (N=30) Source: VEGA-1 TLR Table 14.3.3.2 Continuous Summary of Conjunctival Hyperemia by Time Point (Safety Population) 6 LDP (N=31) Severe (+3) Moderate (+2) Mild (+1) None (0) Scale for Conjunctival Hyperemia CCLRU Reference Ocuphire PHARMA#23P 23 Summary of Positive VEGA-1 Phase 2 Results for Nyxol Eye Drops Efficacy Data In Subjects With A Favorable Safety Profile In Presbyopia With Nyxol And Low Dose Pilocarpine • Met the primary endpoint with statistical significance for binocular photopic near vision at 1 hour 61% Nyxol + LDP gained 15 letters (3 lines) or more vs. 28% Placebo (33% Placebo Adjusted) • Met the Phase 3 co-primary endpoint vs. placebo gaining 15 letters (3 lines) near vision with less than 5 letters of distance vision loss ● ● Met many key secondary endpoints Rapid onset at 30 min - - - - Durable near vision improvement through at least 6 hours Nyxol+LDP was numerically better than each component through 2-hours Sustained significant reduction in PD over at least 18 hours due the durability effects of Nyxol Near vision efficacy seen monocularly and binocularly Also, efficacy data in both light and dark iris colors Favorable safety profile for Nyxol + LDP No serious AEs No systemic AEs were observed in >5% subjects No headaches, no browaches, and no blurry vision AEs were reported Only mild, transient conjunctival hyperemia observed in <5% of subjects Positive Phase 2 results lead to advancing Phase 3 presbyopia program - VEGA-1 Topline Reports (TLR) Ocuphire PHARMA#24P 24 Next Steps Ocuphire Plans To Present Full Results At ASCRS In July And Move Into Phase 3 VEGA-1 Presbyopia Presentation by Dr. Pepose at ASCRS on Sunday July 25, 2021 at 8:45am ASCRS Paper ID 76645 SPS-204 Presbyopia Correcting IOL Comparisons, New Treatments and Studies MBCR - Level 2, Lagoon EF MIRA-2 Reversal of Mydriasis Presentation by Dr. Pepose at ASCRS on Monday July 26, 2021 at 4:25pm ASCRS Paper ID 76599 SPS-316 Corneal Diagnostic Studies MBCR-Level 2, Lagoon EF Advance into Phase 3 Presbyopia Registration Trials in 2022 Towards a Potential NDA in 2023 Ocuphire PHARMA#2525 Presbyopia Market Opportunity Ocuphire PHARMA#26P 26 Presbyopia - Chronic Opportunity Aging Population Drives Demand for Alternatives to Reading Glasses & Very Large Market ● ● The Problem Lens loses ability to change shape when viewing objects up close as we age Dependence on reading glasses for intermittent and prolonged use Growing need for therapies that improve, rather than hinder, quality of life ee Effectively everyone over 40 will have the problems with reading.99 Physician KOL Source: GlobalData Market Research Report, 2020 No Currently Approved Drug Therapies 120 M Patients Seeking Treatment Findings -$5B Market Opportunity Patients requesting alternative to reading glasses Patients would consider an eye drop alternative 40% 69% Ocuphire PHARMA#27P 27 Presbyopia - Chronic Opportunity Pupil Modulation Eye Drops May Replace Reading Glasses ● ● Nyxol's Potential Differentiated Solution "Pin-hole" effect of Nyxol and low dose pilocarpine may improve near vision by increasing depth of focus as validated by other devices/therapies More durable combination of two miotics affecting different muscles (iris dilator and sphincter) involved in pupil size modulation Tolerable use with minimal side effects expected with chronic evening use of Nyxol ee This would just become part of my daily routine for my eyes to be able to see things up close. How convenient is that? ⁹⁹ 99 Presbyopic Patient, age 49 Retinaeyedoctor.com, GlobalData Market Research Report, 2020 Large Pupil Pin-hole Pupil Near FOCUS FOCUS In focus Far In focus Ocuphire PHARMA#28P Synergistic Effects of Nyxol + Low-Dose Pilocarpine (LDP) Combo Nyxol + LDP Demonstrated Efficacy and a Favorable Safety Profile in VEGA-1 Trial 0.75% Nyxol Average PD in photopic conditions is 3.5 to 4.5 mm 28 F O 0.4% 0.4% LDP Source: Ocuphire Clinical Trials Iris Dilator Muscle Inhibition -0.7 to 1+ mm Reduction in PD¹ -1 to 1.5+ mm Reduction in PD Iris Sphincter Muscle Activation Flori Opal Solution, 0.4% Nyxol + LDP 1.5 to 2.5 mm PD reduction moves toward the pin-hole (1.6 to 2.5 mm, up to <3 mm) ≥ 3-line improvement in near vision expected Benefits of Nyxol + LDP: Observed longer durability of effect → inhibition of the dilator muscle with Nyxol may allow sphincter muscle to constrict without opposition and the long-acting effects of Nyxol Lower dose of pilocarpine showed a moderate miotic effect on sphincter muscle Lower dose of pilocarpine showed reduced known side effects such as headaches, browaches, and day/night distance loss Ocuphire PHARMA#29P 29 Presbyopia Eye Drops Competitive Landscape Validation of Pupil Modulating Drops Achieving Pin-Hole Effect & Efficacy, Many with Pilocarpine Pupil modulation MOA Soften lens MOA Combination drugs *act on sphincter and ciliary muscles in dose- dependent manner Cholinergic Agonist* (pilocarpine) Other Cholinergic Agonists* Visus (BrimocholⓇ; brimonidine + carbachol) Orasis (CSF-1; Low dose pilo) Allergan (AGN-190584; 1.25% pilo) Eyenovia (MicroLine; 1 or 2% pilo) NDA Phase 3 Phase 2 Phase 1 Lenz (PRX-100; aceclidine) Novartis (EV-06) Ocuphire (0.75% Nyxol + 0.4% pilo) Ocuphire is differentiated by using both the dilator and sphincter muscles moderately to reach a pin-hole pupil size Alpha Antagonist & pilocarpine* Corporate Websites, Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020 Ocuphire PHARMA#30P 30 Potential 'Best in Class' Presbyopia Drop Competitive Approaches Limited by Safety/Tolerability, Durability, and Poor Distance Night Vision Nyxol + LDP Presbyopia Treatment is Differentiated: ✓ Statistically significant efficacy data ✓ Favorable safety profile ✓ Comfort and tolerability ✓ Fast onset ✓ Long duration ✓ Maintain good distance visual acuity (night/day) ✓ Novel tunable pupil modulation Ocuphire PHARMA#3131 Future Milestones Ocuphire PHARMA#32P 32 2021 to 2022 Ocuphire Cadence of Milestones Multiple Data Catalysts On Path To NDA(s) 2020 Completion of APX3330 License ARVO 2020 Presentation for MIRA-1 & ORION-1 FDA EOP2 Meeting May 2020 Completion of Transaction (Nasdaq: OCUP) and concurrent $20M financing Initiate Phase 3 RM Trial Initiate Phase 3 NVD Trial Complete Nyxol Market Research Journal Publications 1H 2021 Enrollment of Phase 3 RM Trial Initiate Phase 2 Presbyopia Trial Report Positive Phase 3 Data for RM Initiate Phase 2 DR/DME Trial Enrollment of Phase 2 Presbyopia Trial New Patent Claims Closed $15M registered direct offering Report Positive Phase 2 Data for Presbyopia 2H 2021 *Additional Studies for NVD and DR based on Data Readouts ASCRS 2021 Presentation for MIRA-2 & VEGA-1 Initiate 2nd P3 RM and Pediatric RM trial for NDA O Enrollment of Phase 3 NVD Trial Report Phase 3 Data for NVD Enrollment of Phase 2 DR/DME Trial Industry Conferences & Publications Manufacture 3xRegistration Batches for Nyxol Blow-Fill- Seal (BFS) Eye Drops Complete 6-month Rabbit Tox Study 2022* Report 2nd Ph3 RM Trial Report Pediatric RM trial Report Phase 2 Data for DR/DME Initiate 2 Phase 3 Presbyopia Trials Initiate Chronic Ph3 Safety Trial (Nyxol/LDP) Complete 1 year CMC stability on 3xreg batches Submit Nyxol NDA filing for RM in late 2022 Manufacture Commercial Batches of Nyxol Eye Drop Ongoing partnering discussions with leading ophthalmic companies (including European and Asian players) 2023* Report Phase 3 Data for Presbyopia Trials Potential NDA for Nyxol in RM Potential Commercial Launch of Nyxol in US Submit NDA filing for Nyxol for Presbyopia in 2023 Ocuphire PHARMA#33Ocuphire Restore Vision & Clarity Q&A www.ocuphire.com [email protected]